What FDA regulatory classification governs PRP kits and what does that mean for a practice?

Here’s the part most clinics get wrong before they buy their first kit: the FDA cleared the hardware, not the treatment. A PRP kit sits on the shelf as a Class II medical device, cleared through the 510(k) pathway to spin down a small blood sample into platelet concentrate, but the platelets you inject ride in a separate regulatory bucket as a human cell or tissue product under 21 CFR Part 1271. That split is what shapes which kit you buy, how the consent form reads, what your website can say, and how you talk to a patient about cash-pay PRP.

• Cleared device, not approved therapy: The kit’s 510(k) covers the centrifuge, tube, and protocol, not the clinical use of PRP.
• 361 HCT/P pathway: PRP qualifies as minimally manipulated, homologous, same-visit, same-patient autologous tissue.
• Off-label injection is legal but unfunded: Knee, tendon, scalp, and skin uses sit outside the label, and insurance treats them as experimental.
• Marketing is tightly bounded: You can describe the procedure and the cleared device, but you can’t claim FDA approval for any condition.

Under what FDA framework is a PRP kit cleared and what does that framework actually regulate?

The kit lives under product code JQC, the same code FDA uses for automated blood cell separators, and it clears the market through the 510(k) substantial-equivalence pathway run by the Center for Devices and Radiological Health. That clearance is about safe blood handling, not clinical efficacy, which is why two centers of the FDA end up touching one procedure: CDRH owns the kit, and the Center for Biologics Evaluation and Research owns the platelets the kit produces. This split jurisdiction is where most field confusion starts.

• Product code JQC, 510(k) pathway: Substantial-equivalence clearance against a predicate centrifuge or apheresis system, not a novel reference.
• Scope of the clearance: Covers the centrifuge, tube, anticoagulant, separation gel, and labeled processing protocol that yields a defined platelet concentration.
• What it doesn’t cover: The resulting PRP as a therapeutic product, which sits with CBER under 21 CFR Part 1271.
• Manufacturer obligations: Quality System Regulation in 21 CFR Part 820, sterility and biocompatibility validation, establishment registration, device listing, and Medical Device Reports for deaths or serious injuries.

Why is PRP itself not approved as a drug or biologic by the FDA and how does the 361 HCT/P pathway fit in?

PRP dodges the heavy drug and biologic approval pathway because Congress and the FDA carved out autologous tissue that’s processed and returned to the same patient in a single visit. That carve-out lives in Section 361 of the Public Health Service Act, implemented through 21 CFR Part 1271, and it has four hard gates the product has to clear at the same time. Step outside any one of them and PRP stops being a 361 product and becomes a Section 351 biologic, which means an Investigational New Drug application, controlled trials, and a Biologics License Application that no one in PRP has ever pursued.

1. Minimally manipulated: Centrifugation and concentration are fine, but you can’t expand cells in culture or alter the biological characteristics.
2. Homologous use: The product has to be used for the same basic function it serves in the donor.
3. No combination with another article: You can use sterilants, preservatives, and water, but you can’t add growth factors or non-autologous biologics.
4. Autologous, same surgical procedure: Drawn and reinfused into the same patient at the same visit, with no banking between visits.

What is the difference between FDA clearance of the kit and FDA approval of the PRP treatment, and why does that distinction matter clinically?

Conflating “cleared” and “approved” is the single most common compliance error on a PRP practice website. Clearance and approval are two different agency actions with two different evidence bars, and getting the language wrong is what triggers misleading-advertising letters. Here’s the working comparison every clinician and marketing lead should have in their head before they touch a homepage.

What does the cleared 510(k) indication for a PRP kit actually say, and how does that constrain on-label use?

You can read the actual Indications for Use language by pulling the kit’s 510(k) summary from FDA’s public database, and the words on that page are narrower than most practices realize. Typical phrasing centers on intraoperative mixing of PRP with bone graft to improve handling, which means essentially every injection a pain or orthopedic clinic performs is off-label use of the device. Off-label is legal, but it’s the physician’s clinical judgment carrying the weight, not the kit’s label.

• Typical labeled scope: Safe and rapid preparation of autologous PRP from a small blood sample at the point of care for mixing with autograft or allograft bone.
• Off-label by default: Knee osteoarthritis, lateral epicondylitis, rotator cuff tendinopathy, plantar fasciitis, hair restoration, and facial aesthetics all sit outside that scope.
• What manufacturers can’t do: Sales reps cannot promote off-label indications, distribute off-label clinical literature outside the unsolicited-request safe harbor, or train physicians on off-label injection technique.
• Where to verify: FDA’s 510(k) database, searchable by K-number, where the clearance letter and summary are public records.

How does off-label clinical use of PRP intersect with FDA authority over the physician practice of medicine?

The FDA regulates products in interstate commerce; state medical boards regulate physicians. That’s the line, and it’s been the agency’s consistent position for decades. A licensed physician can inject PRP into an arthritic knee even though no PRP product is approved for that indication, because the practice-of-medicine doctrine puts that decision in the physician’s lap. But the line isn’t absolute, and there are three scenarios where FDA reasserts its jurisdiction.

What promotional and marketing claims can a practice legally make about PRP given the kit’s regulatory status?

Two agencies share oversight of medical advertising: the FDA on behalf of device manufacturers and labeled indications, and the FTC on behalf of consumers under the deceptive-advertising standard. The FTC requires that any health claim be supported by competent and reliable scientific evidence, which for a clinical outcome means well-designed human studies. That’s the standard your website copy has to meet, and the phrases below are the ones that most reliably draw a regulator’s eye.

• Phrases that trigger enforcement: “FDA-approved PRP,” “cure for arthritis,” “regrows cartilage,” “guaranteed results,” and any language implying official endorsement.
• Defensible framing: Describe the procedure mechanically, note the kit is FDA-cleared, summarize what published studies have found while acknowledging mixed evidence, and tie outcome claims to specific cited studies.
• Before-and-after photos: Need to be representative, consented, free of digital alteration, and accompanied by individual-variation disclaimers.
• Patient testimonials: Treated as the practice’s own advertising claims under FTC rules, so an unverifiable patient statement becomes a deceptive claim by the clinic.

What documentation, consent language, and recordkeeping does the FDA framework effectively force a practice to maintain?

Even though FDA doesn’t inspect a private orthopedic or pain office, the regulatory framework around PRP forces a paper trail that protects you in malpractice, board investigations, and any FDA inquiry into the manufacturer’s customer base. The work falls into three stacks: the procedure record, the consent form, and the 361 HCT/P boundary evidence. Build all three into the workflow once and you stop scrambling later.

1. Procedure record: Document kit manufacturer, lot number, expiration date, blood volume drawn, centrifuge protocol, resulting PRP volume, injection site and technique, imaging guidance, and any activators like calcium chloride or thrombin.
2. Informed consent: State explicitly that FDA has not approved PRP for the patient’s condition, the use is off-label, the kit is cleared as a device, the evidence base is described as supportive or mixed, insurance won’t cover it, and alternatives including doing nothing were discussed.
3. 361 HCT/P boundary evidence: Make clear in the chart that blood was drawn and PRP reinfused into the same patient at the same visit with no banking, transfer, or storage, and no non-autologous additives outside the kit’s labeled additives.
4. Retention: Keep records for the longer of the manufacturer’s recommendation, the state’s medical record retention statute (typically seven to ten years for adults, longer for minors), and the malpractice statute of limitations.
5. Adverse event reporting: Report infection, severe pain, allergic reaction, or unexpected outcomes to the kit manufacturer and file directly with MedWatch; cumulative reporting is what lets FDA detect patterns.

How do state medical boards and CMS reimbursement rules layer on top of the FDA classification of a PRP kit?

FDA classification is one layer of a four-layer regulatory stack you actually have to work inside. State medical boards govern the clinician, CMS and commercial payers govern the billing, and state regenerative medicine statutes govern the marketing in certain jurisdictions. The reimbursement layer is where the FDA classification has the most practical consequence, because Medicare’s evidence threshold for medical necessity isn’t met by the current PRP literature for musculoskeletal indications.

What enforcement actions has the FDA taken against PRP clinics or device makers, and what patterns do those cases reveal?

FDA hasn’t pursued widespread enforcement against individual physician practices for off-label PRP injection, consistent with its hands-off posture on the practice of medicine, but it has acted hard against clinics and manufacturers that crossed into product manufacturing or unapproved-product promotion. The clearest case law comes from the broader regenerative space, where federal court injunctions against stem cell clinics in California and Florida laid down standards that apply directly to any PRP operation doing similar things.

• Landmark case: United States v. US Stem Cell Clinic established that processing autologous tissue in ways that breach minimal manipulation and homologous use under 21 CFR 1271 triggers full FDA jurisdiction.
• Warning Letter triggers: Approved/cleared claims for unapproved indications, manufacturing without establishment registration, failure to operate under good manufacturing practices, and misleading website claims about cures or guaranteed outcomes.
• Self-audit red flags: Website language using “approved,” “cure,” or “regenerate”; social media outcome claims unsupported by published evidence; banking PRP across visits; non-autologous growth factors or scaffolds; sales of PRP doses to other clinics.
• FTC parallel track: Operation Cure-All and subsequent stem cell sweeps reached deceptive advertising of regenerative therapies, working alongside FDA on the marketing side.